Medivir
3.24 SEK +6.23%1 investor is following this company
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Revenue
7.6M
EBIT %
-1,202.63 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MVIR
Daily low / high price
2.91 / 3.3
SEK
Market cap
365.85M SEK
Turnover
1.36M SEK
Volume
441K
Latest videos
Financial calendar
Interim report
30.04.2024
General meeting
07.05.2024
Interim report
22.08.2024
Interim report
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 12.2 % | 12.2 % |
Avanza Pension | 9.8 % | 9.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools